Chandigarh Herald

Cone Rod Dystrophy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Retina Implant, Dompe Pharmaceuticals and many others

 Breaking News
  • No posts were found

Cone Rod Dystrophy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Retina Implant, Dompe Pharmaceuticals and many others

September 16
02:37 2023
Cone Rod Dystrophy  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Retina Implant, Dompe Pharmaceuticals and many others
DelveInsight Business Research LLP
DelveInsight’s ‘Cone Rod Dystrophy—Competitive Landscape and Market Forecast–2032’ report delivers an in-depth understanding of the TIM-3 as well as the market trends of Cone Rod Dystrophy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight’s ‘Cone Rod Dystrophy—Competitive Landscape and Market Forecast–2032’ report delivers an in-depth understanding of the TIM-3 as well as the market trends of Cone Rod Dystrophy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Highlights of the Cone Rod Dystrophy Market 

  • The Key Companies working in the Cone Rod Dystrophy market include Retina Implant AG, Dompe Pharmaceuticals, and many others 

  • The Key Therapies working in the Cone Rod Dystrophy market include rhNGF, SPVN06, and many others.

Cone Rod Dystrophy Overview

Cone–rod dystrophies are a group of progressive diseases in which cone dysfunction occurs first, followed by rod degeneration. Early changes in the macula are observed in affected individuals. Symptoms include decreased visual acuity, color vision defects, and decreased sensitivity in the central visual field.

Cone rod Dystrophy refers to a series of inherited retinal disorders with earlier or predominantly cone impairment and concurrent or subsequent less severe rod impairment. CORD is usually hard to differentiate with cone dystrophy, whereas some cone dystrophy may actually be the early stage of Cone Rod Dystrophy  and may subsequently develop to CORD with aging. Patients with CORD usually have reduced visual acuity, photophobia, color vision defects, central scotomata, with or without nystagmus, and absent or severely reduced cone responses accompanied by less severe rod impairment on ERG recordings. Fundus changes may vary from normal-looking to fine macular lesions, macular atrophy, macular pigmentation, narrowing arteries, and optic disc pallor. At a late stage, Cone Rod Dystrophy  may progress to generalized retinal degeneration involving both posterior and peripheral fundus, which might be indistinguishable from retinitis pigmentosa.

Cone Rod Dystrophy  Epidemiology Insights

  • Cone Rod dystrophy prevalence 1/40,000 are inherited retinal dystrophies that belong to the group of pigmentary retinopathies. Cone rod dystrophy is characterized by retinal pigment deposits visible on fundus examination, predominantly localized to the macular region.

Click here to learn more about the Cone Rod Dystrophy Market Landscape

The Report Covers the Cone Rod Dystrophy  Epidemiology Segmented by:

  • Cone Rod Dystrophy  diagnosed cases 

  • Total Cone Rod Dystrophy incident cases

  • Total Cone Rod Dystrophy prevalent cases 

  • Cone Rod Dystrophy treatment cases 

Cone Rod Dystrophy Market Outlook 

The Cone Rod Dystrophy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cone Rod Dystrophy market trends by analyzing the impact of current Cone Rod Dystrophy therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Cone Rod Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cone Rod Dystrophy market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Cone Rod Dystrophy market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Cone Rod Dystrophy Market

  • Retina Implant AG

  • Dompe Pharmaceuticals

And many others 

Cone Rod Dystrophy Therapies Covered and Analyzed in the Report

  •  rhNGF

  • SPVN06

And many others.

 Learn more about the Key Companies and Emerging Therapies in the Cone Rod Dystrophy Market

 Table of Contents 

  1. Key Insights 

  2. Cone Rod Dystrophy  Introduction 

  3. Executive Summary of Cone Rod Dystrophy           

  4. Disease Background and Overview

  5. Epidemiology and Patient Population

  6. Cone Rod Dystrophy  Emerging Therapies

  7. Cone Rod Dystrophy  Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Cone Rod Dystrophy Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services